Abstract:Abstract ONC201 is a promising anti-cancer agent that kills tumor cells by triggering an integrated stress response (ISR) dependent on ATF4. ONC201 demonstrated tumor regression and prolonged disease stability in patients with histone H3K27M-mutated midline glioma. The Enhancer of Zeste Homolog 2 (EZH2), a subunit of the polycomb repressive complex 2 (PRC2), is a histone methyltransferase that tri-methylates H3K27 (H3K27me3) and silences target genes. EZH2 inhibitors (EZH2i) reduce global H3K27 methylation. Based on the fact that the H3K27 mutation reduces H3K27 dimethylation (H3K27me2) and trimethylation (H3K27me3), we hypothesized that ONC201 sensitivity and tumor cell death may be enhanced by reducing H3K27 methylation with EZH2i as a mimic of H3K27M-mutation and by increasing H3K27 acetylation with histone deacetylase inhibitors (HDACi). We evaluated synergy of EZH2i EPZ-6438 or HDACi vorinostat with ONC201 against GBM cell lines, U251 and T98G-1 and DMG cell line, SF8638. Cell viability was determined with the Cell Titer Glo assay. Apoptosis was evaluated through immunoblotting of cleaved PARP and flow cytometry analysis of cell distribution. ISR activity was evaluated using immunoblotting of ATF4. Our result demonstrate that ONC201 synergistically reduced cell viability with vorinostat in U251, T98G-1 and SF8628 cell lines, induced apoptosis in combination with vorinostat in U251 and SF8628. ONC201 synergistically reduced cell viability and induced apoptosis with EPZ-6438 in U251. The immunoblotting detected no enhancement of ATF4 by addition of EPZ-6438 to ONC201. Immunoblotting analysis showed that EPZ-6438 reduced H3K27me3 in U251. Our results unravel potent synergy between ONC201 and EZH2i or HDACi in GBM and DMG cell lines, and provide further insights into the role of H3K27me3 in ONC201 drug sensitivity.

What problem does this paper attempt to address?

Based on the provided abstract content, the problems that the paper attempts to solve can be summarized as follows: ### Research Background and Problem Description #### 1. **Evaluation of the Efficacy of Everolimus in Progressive or Recurrent pLGGs (Low - grade Gliomas)** - **Objective**: Estimate the 6 - month progression - free survival rate (PFS6) after Everolimus treatment, and determine whether the activation state of the PI3K/Akt/mTOR pathway (by detecting the state of phosphorylated ribosomal protein S6, i.e., p - RPS6) is related to the treatment response. - **Methods**: The study recruited patients with recurrent or progressive pLGG aged 3 to 21 years. Patients took Everolimus orally at a daily dose of 5 mg/m². All patients were required to provide tissue samples for molecular analysis, and immunohistochemical detection of p - RPS6 was carried out centrally. The Simon two - stage adaptive design was used, and the enrollment criteria for the second stage were adjusted according to the p - RPS6 state. #### 2. **Study on the Resistance Mechanism of BRAF Inhibitors** - **Background**: Although targeted therapies for BRAF - mutated gliomas are effective in some glioma patients, over time, patients may develop resistance. There is currently no detailed description and verification of the resistance mechanism in BRAF - mutated gliomas. - **Methods**: Patient samples before and after treatment with BRAF inhibitors (BRAFi) or BRAFi/MEK inhibitors (MEKi) were collected, and targeted DNA sequencing or whole - exome sequencing (WES) and RNA sequencing were carried out. Potential resistance mechanisms were verified in the established BRAF V600E - mutated glioma cell line. #### 3. **The Potential of Cannabis - derived Extracellular Vesicles (EVs) as an Anti - glioblastoma (GBM) Therapy** - **Hypothesis**: It is hypothesized that cannabis EVs are rich in cannabinoids, and their application can reduce the progression of GBM tumors. - **Methods**: EVs were isolated from cannabis plants and characterized by nanoparticle tracking analysis, electron microscopy, and liquid chromatography - tandem mass spectrometry (LC - MS/MS). The anti - tumor effects of EVs on GBM cell lines were evaluated in neurosphere culture experiments, and the brain tissue distribution of fluorescent - labeled EVs was studied in an orthotopic GBM xenograft model. #### 4. **The Effect of PARP Inhibitors in Combination with Temozolomide (TMZ) in the Treatment of H3 K27M - mutated Diffuse Midline Glioma (DMG)** - **Objective**: Evaluate whether PARP inhibitors can enhance the sensitivity of TMZ to H3 K27M - mutated DMG. - **Methods**: Using the patient - derived DMG cell line SF8628, the cell proliferation inhibitory effects of various PARP inhibitors (such as talazoparib, olaparib, etc.) alone and in combination with TMZ were tested, and the cytotoxicity of the combination treatment was evaluated by apoptosis analysis. #### 5. **The Synergistic Effect of ONC201 in Combination with Epigenetic Modifiers (such as EZH2 Inhibitors or HDAC Inhibitors) in the Treatment of GBM and DMG** - **Background**: ONC201 is an anticancer drug that kills tumor cells by triggering the integrated stress response (ISR) in an ATF4 - dependent manner and has shown efficacy in patients with H3K27M - mutated midline gliomas. - **Methods**: The synergistic effects of EZH2 inhibitors (EPZ - 6438) or HDAC inhibitors (vorinostat) in combination with ONC201 on GBM and DMG cell lines were studied, including cell viability assays, apoptosis analysis, and ISR activity assessment. #### 6. **Preliminary Clinical Experience of Osimertinib in Patients with EGFR - altered Recurrent Malignant Gliomas** - **Background**: EGFR alterations are common in malignant gliomas (especially glioblastomas), making EGFR an attractive therapeutic target. Osimertinib, as a third - generation irreversible EGFR - TKI, can effectively penetrate the blood - brain barrier and reach therapeutic concentrations in brain tissue. - **Methods**: The safety and efficacy of Osimertinib treatment in 6 patients with EGFR - altered recurrent malignant gliomas were retrospectively analyzed. #### 7. **Development of CAR - T Cell Therapies Targeting EGFRvIII and EGFR for the Treatment of Glioblastoma Multiforme

DDRE-16. SYNERGISTIC TUMOR SUPPRESSION FROM COMBINATION OF ONC201 AND EPIGENETIC MODULATORS EZH2 OR HDAC INHIBITOR PROVIDES A NOVEL TREATMENT STRATEGY FOR GBM AND DMG

Abstract 2671: Imipridones ONC201 and ONC206 reduce expression of neogenin and EZH1/2 which correlate with synergy following their combination with EZH1/2 or HDAC inhibitors in treatment of DMG and other tumors

Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists

Abstract 7226: Synergy between ONC201 and temozolomide on ATF4 integrated stress response in glioblastoma

Abstract 3331: Preclinical combination of ONC206 with radiotherapy and temozolomide in a GBM mouse orthotopic model

Enhanced Efficacy of Histone Deacetylase Inhibitor Combined with Bromodomain Inhibitor in Glioblastoma

Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways

Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelial-mesenchymal transition, migration, and on the pro-inflammatory phenotype

Combination of Imipridone ONC201 or ONC206 with Temozolomide and Radiotherapy in triple ITR therapy reduces intracranial tumor burden and prolongs survival in an orthotopic wild-type IDH GBM mouse model

Abstract 4898: Imipridones and EZH2 inhibitors induce similar changes in cytokines and regulated genes in GBM and DMG while vorinostat potentiates anti-tumor efficacy despite variability in cytokine profiles

Abstract B018: Epigenetic targeting improves glioblastoma cell sensitivity to chemotherapy

EPIC-0628 abrogates HOTAIR/EZH2 interaction and enhances the temozolomide efficacy via promoting ATF3 expression and inhibiting DNA damage repair in glioblastoma

Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas

Abstract 4659: Depicting ONC201/Delta-24-RGD combination for the treatment of pHGGs and DMGs reveals a therapeutic benefit and a proinflammatory tumor microenvironment remodelation

Dddr-36. Looking Around The Corner: Predicting Synergy Or Futility To Combination Of Arsenic Trioxide Plus Mnk1 Inhibitors In Glioblastoma

BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma

Abstract A012: EZH2 as a therapeutic target for glioma

Enhanced Efficacy of Histone Deacetylase Inhibitor Panobinostat Combined with Dual PI3K/mTOR Inhibitor BEZ235 Against Glioblastoma

Combination LSD1 and HOTAIR-EZH2 Inhibition Disrupts Cell Cycle Processes and Induces Apoptosis in Glioblastoma Cells

Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo

EXTH-19. OPTIMIZING MDM2 INHIBITION FOR THE TREATMENT OF GLIOBLASTOMA